4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders (2020 - 2025)
Historic Net Income towards Common Stockholders for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$56.9 million.
- 4D Molecular Therapeutics' Net Income towards Common Stockholders fell 2972.65% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.2 million, marking a year-over-year decrease of 4578.83%. This contributed to the annual value of -$160.9 million for FY2024, which is 5953.27% down from last year.
- Latest data reveals that 4D Molecular Therapeutics reported Net Income towards Common Stockholders of -$56.9 million as of Q3 2025, which was down 2972.65% from -$54.7 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Net Income towards Common Stockholders ranged from a high of -$7.6 million in Q2 2021 and a low of -$56.9 million during Q3 2025
- In the last 5 years, 4D Molecular Therapeutics' Net Income towards Common Stockholders had a median value of -$28.7 million in 2023 and averaged -$31.6 million.
- Per our database at Business Quant, 4D Molecular Therapeutics' Net Income towards Common Stockholders skyrocketed by 6007.94% in 2023 and then tumbled by 32748.63% in 2024.
- 4D Molecular Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$25.1 million in 2021, then fell by 9.15% to -$27.4 million in 2022, then decreased by 17.91% to -$32.3 million in 2023, then tumbled by 53.86% to -$49.7 million in 2024, then decreased by 14.51% to -$56.9 million in 2025.
- Its last three reported values are -$56.9 million in Q3 2025, -$54.7 million for Q2 2025, and -$48.0 million during Q1 2025.